Investigating macrophage-mediated inflammation in migraine using ultrasmall superparamagnetic iron oxide-enhanced 3T magnetic resonance imaging
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Investigating macrophage-mediated inflammation in migraine using ultrasmall superparamagnetic iron oxide-enhanced 3T magnetic resonance imaging. / Khan, Sabrina; Amin, Faisal Mohammad; Fliedner, Frederikke Petrine; Christensen, Casper Emil; Tolnai, Daniel; Younis, Samaira; Olinger, Anne Christine Rye; Birgens, Henrik; Daldrup-Link, Heike; Kjær, Andreas; Larsson, Henrik Bo Wiberg; Lindberg, Ulrich; Ashina, Messoud.
In: Cephalalgia, Vol. 39, No. 11, 2019, p. 1407-1420.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Investigating macrophage-mediated inflammation in migraine using ultrasmall superparamagnetic iron oxide-enhanced 3T magnetic resonance imaging
AU - Khan, Sabrina
AU - Amin, Faisal Mohammad
AU - Fliedner, Frederikke Petrine
AU - Christensen, Casper Emil
AU - Tolnai, Daniel
AU - Younis, Samaira
AU - Olinger, Anne Christine Rye
AU - Birgens, Henrik
AU - Daldrup-Link, Heike
AU - Kjær, Andreas
AU - Larsson, Henrik Bo Wiberg
AU - Lindberg, Ulrich
AU - Ashina, Messoud
PY - 2019
Y1 - 2019
N2 - Background: Initiating mechanisms of migraine headache remain poorly understood and a biomarker of migraine does not exist. Inflammation pertaining to the wall of cerebral arteries and brain parenchyma has been suggested to play a role in migraine pathophysiology. Objective: We conducted the first experimental human study to investigate macrophage-mediated inflammation as a possible biomarker of migraine. Methods: Using ultrasmall superparamagnetic iron oxide (USPIO)-enhanced 3T magnetic resonance imaging (MRI), we investigated the presence of macrophages in cerebral artery walls and in brain parenchyma of patients with migraine without aura. We used the phosphodiesterase-3-inhibitor cilostazol as an experimental migraine trigger, and investigated both patients who received sumatriptan treatment, and patients who did not. To validate our use of USPIO-enhanced MRI, we included a preclinical mouse model with subcutaneous capsaicin injection in the trigeminal V1 area. The study is registered at ClinicalTrials.gov with the identifier NCT02549898. Results: A total of 28 female patients with migraine without aura underwent a baseline MRI scan, ingested cilostazol, developed a migraine-like attack, and underwent an USPIO-enhanced MRI scan > 24 hours after intravenous administration of USPIO. Twelve patients treated their attack with 6 mg s.c. sumatriptan, while the remaining 16 patients received no migraine-specific rescue medication. The preclinical model confirmed that USPIO-enhanced MRI detects macrophage-mediated inflammation. In patients, however, migraine attacks were not associated with increased USPIO signal on the pain side of the head compared to the non-pain side. Conclusion: Our findings suggest that migraine without aura is not associated with macrophage-mediated inflammation specific to the head pain side.
AB - Background: Initiating mechanisms of migraine headache remain poorly understood and a biomarker of migraine does not exist. Inflammation pertaining to the wall of cerebral arteries and brain parenchyma has been suggested to play a role in migraine pathophysiology. Objective: We conducted the first experimental human study to investigate macrophage-mediated inflammation as a possible biomarker of migraine. Methods: Using ultrasmall superparamagnetic iron oxide (USPIO)-enhanced 3T magnetic resonance imaging (MRI), we investigated the presence of macrophages in cerebral artery walls and in brain parenchyma of patients with migraine without aura. We used the phosphodiesterase-3-inhibitor cilostazol as an experimental migraine trigger, and investigated both patients who received sumatriptan treatment, and patients who did not. To validate our use of USPIO-enhanced MRI, we included a preclinical mouse model with subcutaneous capsaicin injection in the trigeminal V1 area. The study is registered at ClinicalTrials.gov with the identifier NCT02549898. Results: A total of 28 female patients with migraine without aura underwent a baseline MRI scan, ingested cilostazol, developed a migraine-like attack, and underwent an USPIO-enhanced MRI scan > 24 hours after intravenous administration of USPIO. Twelve patients treated their attack with 6 mg s.c. sumatriptan, while the remaining 16 patients received no migraine-specific rescue medication. The preclinical model confirmed that USPIO-enhanced MRI detects macrophage-mediated inflammation. In patients, however, migraine attacks were not associated with increased USPIO signal on the pain side of the head compared to the non-pain side. Conclusion: Our findings suggest that migraine without aura is not associated with macrophage-mediated inflammation specific to the head pain side.
KW - dura mater
KW - ferumoxytol
KW - Headache
KW - inflammation
KW - meningeal nociceptor
KW - USPIO
U2 - 10.1177/0333102419848122
DO - 10.1177/0333102419848122
M3 - Journal article
C2 - 31104505
AN - SCOPUS:85066874225
VL - 39
SP - 1407
EP - 1420
JO - Cephalalgia
JF - Cephalalgia
SN - 0800-1952
IS - 11
ER -
ID: 236663975